Skip to main
HIMS
HIMS logo

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 29%
Buy 6%
Hold 47%
Sell 12%
Strong Sell 6%

Bulls say

Hims & Hers Health Inc. reported a remarkable total revenue increase of 95.1% year-over-year, driven primarily by a significant 98.3% growth in online revenue, exceeding estimates with $470.8 million. Subscriber growth was also notable, with an increase of 182,000 in the quarter, reaching 2.2 million, reflecting a 45% year-over-year growth, while the average order value rose to $168. Management anticipates that the weight loss segment will contribute approximately 30% of total revenue in fiscal year 2025, signifying a strategic shift toward premium personalized offerings, which have also seen substantial growth within the subscriber base.

Bears say

Hims & Hers Health Inc. faces significant challenges due to increasing competition from venture-backed companies that can aggressively undercut pricing, which may erode Hims & Hers' customer base and compress profit margins. The company's gross margin percentage declined in Q4, reflecting a shift in product mix and reduced pricing strategies that could negatively impact overall profitability. Additionally, rising marketing costs or diminished campaign effectiveness further complicate the financial outlook by straining unit economics and contributing to a lower than anticipated operating margin of 8.9%.

HIMS has been analyzed by 17 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 6% recommend Buy, 47% suggest Holding, 12% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 17 analysts, HIMS has a Hold consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.